|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Herbst RS, Morgensztern D and Boshoff C:
The biology and management of non-small cell lung cancer. Nature.
553:446–454. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Pisters KM: The role of chemotherapy in
early-stage (stage I and II) resectable non-small cell lung cancer.
Semin Radiat Oncol. 10:274–279. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Losanno T, Rossi A, Maione P, Napolitano A
and Gridelli C: Anti-EGFR and antiangiogenic monoclonal antibodies
in metastatic non-small-cell lung cancer. Expert Opin Biol Ther.
16:747–758. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gridelli C, de Castro Carpeno J, Dingemans
AC, Griesinger F, Grossi F, Langer C, Ohe Y, Syrigos K, Thatcher N,
Das-Gupta A, et al: Safety and efficacy of bevacizumab plus
standard-of-care treatment beyond disease progression in patients
with advanced non-small cell lung cancer: The AvaALL randomized
clinical trial. JAMA Oncol. 4:e1834862018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Domagała-Kulawik J: Immune checkpoint
inhibitors in non-small cell lung cancer - towards daily practice.
Adv Respir Med. 86:142–148. 2018. View Article : Google Scholar
|
|
7
|
Horn L, Spigel DR, Vokes EE, Holgado E,
Ready N, Steins M, Poddubskaya E, Borghaei H, Felip E, Paz-Ares L,
et al: Nivolumab versus docetaxel in previously treated patients
with advanced non-small-cell lung cancer: Two-year outcomes from
two randomized, open-label, phase III trials (CheckMate 017 and
CheckMate 057). J Clin Oncol. 35:3924–3933. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Vokes EE, Ready N, Felip E, Horn L, Burgio
MA, Antonia SJ, Arén Frontera O, Gettinger S, Holgado E, Spigel D,
et al: Nivolumab versus docetaxel in previously treated advanced
non-small-cell lung cancer (CheckMate 017 and CheckMate 057):
3-year update and outcomes in patients with liver metastases. Ann
Oncol. 29:959–965. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Herbst RS, Baas P, Kim DW, Felip E,
Pérez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, et al:
Pembrolizumab versus docetaxel for previously treated,
PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010):
A randomised controlled trial. Lancet. 387:1540–1550. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Huang M, Pietanza MC, Samkari A,
Pellissier J, Burke T, Chandwani S, Kong F and Pickard AS: Q-TWiST
analysis to assess benefit-risk of pembrolizumab in patients with
PD-L1-positive advanced or metastatic non-small cell lung cancer.
Pharmacoeconomics. 37:105–116. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Peters S, Kerr KM and Stahel R: PD-1
blockade in advanced NSCLC: A focus on pembrolizumab. Cancer Treat
Rev. 62:39–49. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Dermani FK, Samadi P, Rahmani G, Kohlan AK
and Najafi R: PD-1/PD-L1 immune checkpoint: Potential target for
cancer therapy. J Cell Physiol. 234:1313–1325. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Brahmer J, Reckamp KL, Baas P, Crinò L,
Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE,
Holgado E, et al: Nivolumab versus docetaxel in advanced
squamous-cell non-small-cell lung cancer. N Engl J Med.
373:123–135. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Borghaei H, Paz-Ares L, Horn L, Spigel DR,
Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, et al:
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell
lung cancer. N Engl J Med. 373:1627–1639. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Morgensztern D and Herbst RS: Nivolumab
and pembrolizumab for non-small cell lung cancer. Clin Cancer Res.
22:3713–3717. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Shukuya T and Carbone DP: Predictive
markers for the efficacy of anti-PD-1/PD-L1 antibodies in lung
cancer. J Thorac Oncol. 11:976–988. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hellmann MD, Ciuleanu TE, Pluzanski A, Lee
JS, Otterson GA, Audigier-Valette C, Minenza E, Linardou H, Burgers
S, Salman P, et al: Nivolumab plus ipilimumab in lung cancer with a
high tumor mutational burden. N Engl J Med. 378:2093–2104. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Rizvi NA, Hellmann MD, Snyder A, Kvistborg
P, Makarov V, Havel JJ, Lee W, Yuan J, Wong P, Ho TS, et al: Cancer
immunology. Mutational landscape determines sensitivity to PD-1
blockade in non-small cell lung cancer. Science. 348:124–128. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Jin Y, Dong H, Xia L, Yang Y, Zhu Y, Shen
Y, Zheng H, Yao C, Wang Y and Lu S: The diversity of gut microbiome
is associated with favorable responses to anti-programmed death-1
immunotherapy in chinese patients with NSCLC. J Thorac Oncol.
14:1378–1389. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Herbst RS, Soria JC, Kowanetz M, Fine GD,
Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger
SN, et al: Predictive correlates of response to the anti-PD-L1
antibody MPDL3280A in cancer patients. Nature. 515:563–567. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Petrosyan F, Daw H, Haddad A, Spiro T and
Sood R: Gene expression profiling for early-stage NSCLC. Am J Clin
Oncol. 38:103–107. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Li T, Kung HJ, Mack PC and Gandara DR:
Genotyping and genomic profiling of non-small-cell lung cancer:
Implications for current and future therapies. J Clin Oncol.
31:1039–1049. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chim SS, Wong KK, Chung CY, Lam SK, Kwok
JS, Lai CY, Cheng YK, Hui AS, Meng M, Chan OK, et al: Systematic
selection of reference genes for the normalization of circulating
RNA transcripts in pregnant women based on RNA-Seq data. Int J Mol
Sci. 18:17092017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kamps R, Brandão RD, van den Bosch BJ,
Paulussen AD, Xanthoulea S, Blok MJ and Romano A: Next-generation
sequencing in oncology: Genetic diagnosis, risk prediction and
cancer classification. Int J Mol Sci. 18:3082017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Xu H, Chen X, Lin D, Zhang J, Li C, Zhang
D and Zhang X: Conformance assessment of PD-L1 expression between
primary tumour and nodal metastases in non-small-cell lung cancer.
OncoTargets Ther. 12:11541–11547. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Haragan A, Field JK, Davies MP, Escriu C,
Gruver A and Gosney JR: Heterogeneity of PD-L1 expression in
non-small cell lung cancer: Implications for specimen sampling in
predicting treatment response. Lung Cancer. 134:79–84. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Armato SG III and Nowak AK: Revised
modified response evaluation criteria in solid tumors for
assessment of response in malignant pleural mesothelioma (version
1.1). J Thorac Oncol. 13:1012–1021. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cottrell TR, Thompson ED, Forde PM, Stein
JE, Duffield AS, Anagnostou V, Rekhtman N, Anders RA, Cuda JD,
Illei PB, et al: Pathologic features of response to neoadjuvant
anti-PD-1 in resected non-small-cell lung carcinoma: A proposal for
quantitative immune-related pathologic response criteria (irPRC).
Ann Oncol. 29:1853–1860. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Paluch BE, Glenn ST, Conroy JM,
Papanicolau-Sengos A, Bshara W, Omilian AR, Brese E, Nesline M,
Burgher B, Andreas J, et al: Robust detection of immune transcripts
in FFPE samples using targeted RNA sequencing. Oncotarget.
8:3197–3205. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ritchie ME, Phipson B, Wu D, Hu Y, Law CW,
Shi W and Smyth GK: limma powers differential expression analyses
for RNA-sequencing and microarray studies. Nucleic Acids Res.
43:e472015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
R Core Team: R: A language and environment
for statistical computing. R Foundation for Statistical Computing;
Vienna, Austria: https://www.R-project.org2018
|
|
32
|
Yu G, Wang LG, Han Y and He QY:
clusterProfiler: An R package for comparing biological themes among
gene clusters. OMICS. 16:284–287. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hänzelmann S, Castelo R and Guinney J:
GSVA: Gene set variation analysis for microarray and RNA-seq data.
BMC Bioinformatics. 14:72013. View Article : Google Scholar
|
|
34
|
Qu J, Mei Q, Liu L, Cheng T, Wang P, Chen
L and Zhou J: The progress and challenge of anti-PD-1/PD-L1
immunotherapy in treating non-small cell lung cancer. Ther Adv Med
Oncol. Feb 15–2021.(Epub ahead of print). doi:
10.1177/1758835921992968. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Valecha GK, Vennepureddy A, Ibrahim U,
Safa F, Samra B and Atallah JP: Anti-PD-1/PD-L1 antibodies in
non-small cell lung cancer: The era of immunotherapy. Expert Rev
Anticancer Ther. 17:47–59. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Chen R, Tao Y, Xu X, Shan L, Jiang H, Yin
Q, Pei L, Cai F, Ma L and Yu Y: The efficacy and safety of
nivolumab, pembrolizumab, and atezolizumab in treatment of advanced
non-small cell lung cancer. Discov Med. 26:155–166. 2018.PubMed/NCBI
|
|
37
|
Rizvi NA, Mazières J, Planchard D,
Stinchcombe TE, Dy GK, Antonia SJ, Horn L, Lena H, Minenza E,
Mennecier B, et al: Activity and safety of nivolumab, an anti-PD-1
immune checkpoint inhibitor, for patients with advanced, refractory
squamous non-small-cell lung cancer (CheckMate 063): A phase 2,
single-arm trial. Lancet Oncol. 16:257–265. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Rolfo C, Caglevic C, Santarpia M, Araujo
A, Giovannetti E, Gallardo CD, Pauwels P and Mahave M:
Immunotherapy in NSCLC: A promising and revolutionary weapon. Adv
Exp Med Biol. 995:97–125. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Yi M, Jiao D, Xu H, Liu Q, Zhao W, Han X
and Wu K: Biomarkers for predicting efficacy of PD-1/PD-L1
inhibitors. Mol Cancer. 17:1292018. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Chen G, Huang AC, Zhang W, Zhang G, Wu M,
Xu W, Yu Z, Yang J, Wang B, Sun H, et al: Exosomal PD-L1
contributes to immunosuppression and is associated with anti-PD-1
response. Nature. 560:382–386. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Chen L and Han X: Anti-PD-1/PD-L1 therapy
of human cancer: Past, present, and future. J Clin Invest.
125:3384–3391. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Yang Z, Li H, Wang Z, Yang Y, Niu J, Liu
Y, Sun Z and Yin C: Microarray expression profile of long
non-coding RNAs in human lung adenocarcinoma. Thorac Cancer.
9:1312–1322. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Holmdahl R, Sareila O, Olsson LM, Bäckdahl
L and Wing K: Ncf1 polymorphism reveals oxidative regulation of
autoimmune chronic inflammation. Immunol Rev. 269:228–247. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Kelkka T, Pizzolla A, Laurila JP, Friman
T, Gustafsson R, Källberg E, Olsson O, Leanderson T, Rubin K, Salmi
M, et al: Mice lacking NCF1 exhibit reduced growth of implanted
melanoma and carcinoma tumors. PLoS One. 8:e841482013. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Wu W, Kemp BL, Proctor ML, Gazdar AF,
Minna JD, Hong WK and Mao L: Expression of DMBT1, a candidate tumor
suppressor gene, is frequently lost in lung cancer. Cancer Res.
59:1846–1851. 1999.PubMed/NCBI
|
|
46
|
Mollenhauer J, Helmke B, Müller H,
Kollender G, Lyer S, Diedrichs L, Holmskov U, Ligtenberg T,
Herbertz S, Krebs I, et al: Sequential changes of the DMBT1
expression and location in normal lung tissue and lung carcinomas.
Genes Chromosomes Cancer. 35:164–169. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Raez LE, Cassileth PA, Schlesselman JJ,
Sridhar K, Padmanabhan S, Fisher EZ, Baldie PA and Podack ER:
Allogeneic vaccination with a B7.1 HLA-A gene-modified
adenocarcinoma cell line in patients with advanced non-small-cell
lung cancer. J Clin Oncol. 22:2800–2807. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Leclerc M, Mezquita L, Guillebot De
Nerville G, Tihy I, Malenica I, Chouaib S and Mami-Chouaib F:
Recent advances in lung cancer immunotherapy: Input of T-cell
epitopes associated with impaired peptide processing. Front
Immunol. 10:15052019. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Xiao-Peng H, Fu-Jie S, Xiang-Yan L, Wang
Z, Li XX, Liu FY, Chen G, Jiang WP, et al: The relationship between
KRAS gene mutations and HLA class I antigen downregulation in the
metastasis of non-small cell lung cancer. J Int Med Res.
41:1473–1483. 2013. View Article : Google Scholar
|
|
50
|
Nocentini G, Ronchetti S, Petrillo MG and
Riccardi C: Pharmacological modulation of GITRL/GITR system:
Therapeutic perspectives. Br J Pharmacol. 165:2089–2099. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Tian J, Ma J, Ma K, Ma B, Tang X, Baidoo
SE, Tong J, Yan J, Lu L, Xu H, et al: Up-regulation of GITRL on
dendritic cells by WGP improves anti-tumor immunity in murine Lewis
lung carcinoma. PLoS One. 7:e469362012. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Ma J, Wang S, Ma B, Mao C, Tong J, Yang M,
Wu C, Jiao Z, Lu L and Xu H: Dendritic cells engineered to express
GITRL enhance therapeutic immunity in murine Lewis lung carcinoma.
Cancer Lett. 301:142–150. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Chen R, Khatri P, Mazur PK, Polin M, Zheng
Y, Vaka D, Hoang CD, Shrager J, Xu Y, Vicent S, et al: A
meta-analysis of lung cancer gene expression identifies PTK7 as a
survival gene in lung adenocarcinoma. Cancer Res. 74:2892–2902.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Damelin M, Bankovich A, Bernstein J, Lucas
J, Chen L, Williams S, Park A, Aguilar J, Ernstoff E, Charati M, et
al: A PTK7-targeted antibody-drug conjugate reduces
tumor-initiating cells and induces sustained tumor regressions. Sci
Transl Med. 9:eaag26112017. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Kim JH, Kwon J, Lee HW, Kang MC, Yoon HJ,
Lee ST and Park JH: Protein tyrosine kinase 7 plays a tumor
suppressor role by inhibiting ERK and AKT phosphorylation in lung
cancer. Oncol Rep. 31:2708–2712. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Hughey JJ: Machine learning identifies a
compact gene set for monitoring the circadian clock in human blood.
Genome Med. 9:192017. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Hsu YC, Chiu YC, Chen Y, Hsiao TH and
Chuang EY: A simple gene set-based method accurately predicts the
synergy of drug pairs. BMC Syst Biol. 10 (Suppl 3):662016.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Li N, Hou JL, Shi ZZ, Li XG, Li N, Sun YC,
Xu X, Cai Y, Zhang X, Zhang KT, et al: Copy number changes of
4-gene set may predict early relapse in advanced epithelial ovarian
cancer after initial platinum-paclitaxel chemotherapy. Am J Cancer
Res. 4:285–292. 2014.PubMed/NCBI
|
|
59
|
Li JN, Zhong R and Zhou XH: Prediction of
bone metastasis in breast cancer based on minimal driver gene set
in gene dependency network. Genes (Basel). 10:4662019. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Shen S, Wang G, Zhang R, Zhao Y, Yu H, Wei
Y and Chen F: Development and validation of an immune gene-set
based prognostic signature in ovarian cancer. EBioMedicine.
40:318–326. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Italiano A, Vandenbos FB, Otto J, Mouroux
J, Fontaine D, Marcy PY, Cardot N, Thyss A and Pedeutour F:
Comparison of the epidermal growth factor receptor gene and protein
in primary non-small-cell-lung cancer and metastatic sites:
Implications for treatment with EGFR-inhibitors. Ann Oncol.
17:981–985. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Reinholz MM, Bruzek AK, Visscher DW,
Lingle WL, Schroeder MJ, Perez EA and Jenkins RB: Breast cancer and
aneusomy 17: Implications for carcinogenesis and therapeutic
response. Lancet Oncol. 10:267–277. 2009. View Article : Google Scholar : PubMed/NCBI
|
